The team lead by Sílvia Vilares Conde, from CEDOC-NOVA Medical School, in collaboration with the pharmaceutical company Galvani Bioelectronics, demonstrated through findings in rats that is possible to restore insulin sensitivity and glucose homeostasis, by modulating electrically the carotid sinus nerve, the sensitive nerve that connects the carotid body with the brain.
The study is published in Diabetologia, the journal of the European Association for the Study of Diabetes [EASD].
In 2013, Silvia Vilares Conde and her research group described that the carotid body, a paired organ that is located in the bifurcation of the common carotid artery and that is classically defined as an oxygen sensor, regulates peripheral insulin sensitivity and that its dysfunction is involved in the development of metabolic diseases.
This first study and others afterwards performed by her group in diabetic rats showed that the bilateral resection of the carotid sinus nerve, and therefore the abolishment of the connection between the carotid body and the brain, restore insulin sensitivity and glucose tolerance. Although efficient this surgical irreversible approach has disadvantages, since the carotid body possess other physiological functions as the response to the lack of oxygen (hypoxia) or the adaptation to exercise. Silvia Conde’s team also described that the carotid body is over-activated in animal models of type 2 diabetes, suggesting that decreasing the activity of the organ could be a good therapeutic strategy.
From the partnership with Galvani Bioelectronics (former Glaxo Smith Kline Bioelectronics), the opportunity to electrically modulate the carotid sinus nerve come up. In fact, this work demonstrated that is possible to maintain glucose homeostasis in animals in which electrodes have been implanted in the carotid sinus nerve and submitted to electrical modulation, without significant adverse effects. It has also been demonstrated that the electrical modulation is reversible. Silvia Conde notes that “this work opens the door to the development of a new therapeutic for type 2 diabetes that will provide a long-term management of the disease with negligible adverse effects and interference with daily activities”.
Type 2 diabetes is characterized by insulin resistance and by increased hepatic glucose production that culminates in hyperglycemia. Although a lot of efforts have been performed until the date none therapeutic induce long-term glycaemia control, being expected for the next decades a huge increase in the prevalence of the disease. Thus, this work gives hope to patients with metabolic diseases, as it brings a new approach for the management of type 2 diabetes.
The Latest on: Type 2 diabetes
- Drug found to be safe and effective for treating patients with obesity and type 2 diabeteson January 13, 2021 at 5:17 pm
A new study confirms that treatment with Bimagrumab, an antibody that blocks activin type II receptors and stimulates skeletal muscle growth, is safe and effective for treating excess adiposity and ...
- Low-carb diet could help fight type 2 diabeteson January 13, 2021 at 4:01 pm
A low-carbohydrate diet can help to put type 2 diabetes into temporary remission, a study has found.The research, published in the British Medical Journal, is further evidence that changes to diet may ...
- Short term low carbohydrate diet linked to remission of type 2 diabeteson January 13, 2021 at 3:33 pm
Patients with type 2 diabetes who follow a strict low carbohydrate diet for six months may experience greater rates of remission compared with other recommended diets without adverse effects, suggests ...
- Just 12 weeks on a low-carb diet 'can beat diabetes': Cutting carbohydrates may increase chances of remission in type 2 patients, study findson January 13, 2021 at 3:31 pm
Patients who reduced carbohydrates for 12 weeks were 32 per cent more likely to be in remission six months later compared with those on other recommended diets.
- Six months on a low-carb diet could lead to remission from type 2 diabetes, study findson January 13, 2021 at 3:30 pm
A review of 23 trials comparing low-carb diets to other eating plans found cutting back on carbs for six months led to greater rates of remission.
- Monoclonal Antibody Induces Weight Loss in Type 2 Diabeteson January 13, 2021 at 8:02 am
A human monoclonal antibody that failed in treating muscle-wasting disease may find new life as an anti-obesity and anti-diabetes drug, according to results of a phase II clinical trial. In 75 ...
- Early research shows promise for therapeutics that delay type 2 diabeteson January 13, 2021 at 6:29 am
Vanderbilt researchers have discovered a unique pathway that initiates islet β cell inflammation—a hallmark of type 2 diabetes—putting them a step closer to developing targeted therapeutics for the ...
- Type 2 diabetes: Simple sugars could contribute to feelings of fatigue - what are they?on January 13, 2021 at 4:16 am
TYPE 2 DIABETES could have you walking through life in a zombie-like state. Feelings of fatigue may intensify as blood sugar levels skyrocket. Simple sugars could be making it worse too, but what are ...
- Diabetes type 2 symptoms: The warning signs when you wake up in the morningon January 12, 2021 at 8:00 pm
DIABETES type 2 does not announce itself with a thunderous force, rather, the symptoms are subtle. You may be met with a number of symptoms when you wake up in the morning.
- Type 2 Diabetes Mellitus Treatment Market Trends Analysis, Future Insights, Size Value, Key Players, SWOT Analysis By 2023on January 12, 2021 at 3:03 pm
Market Scope The developments in type two diabetes mellitus treatments are anticipated to benefit the pharmaceutical firms ...
via Google News and Bing News